Table 1 Patient and tumour characteristics.
Pat 1 | Pat 2 | Pat 3 | Pat 4 | Pat 5 | Pat 6 | Pat 7 | |
|---|---|---|---|---|---|---|---|
Sex | F | M | F | F | M | M | F |
Location of primary tumour | Right | Right | Left | Right | Rectum | Rectum | Right |
T stage | 3c | 4b | 4b | 4a | 4a | 4a | 4b |
N stage | 2b | 2a | 2b | 2b | 2b | 2b | 2b |
Synchronous carcinosis | Y | Y | Y | Y | Y | Y | Y |
Other distant metastases at diagnosis | Liver | ||||||
PCI Score | 8 | 13 | 8 | 24 | 13 | 4 | 9 |
CEA before surgery | 231 | 10 | 2 | - | 3 | 3 | 73 |
Completeness of cytoreduction | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IP treatment | EPIC | HIPEC | HIPEC | HIPEC | HIPEC | HIPEC | HIPEC |
Histology | Signet-ring cell carcinoma | Adenocarcinoma | Mucinous adenocarcinoma | Adenocarcinoma | Adenocarcinoma* | Signet-ring cell carcinoma | Adenocarcinoma |
Overall survival (months) | 98 | 28 | 94 | 14 | 32 | 80 | 78 |
Vital status | 1 | 0 | 1 | 0 | 0 | 1 | 1 |
Adjuvant chemotherapy | Y | Y | Y | N | Y | Y | Y |
Number of samples IHC | 53 | 52 | 41 | 69 | 70 | 50 | 68 |
Number of samples TDS | 9 | 19 | 5 | 16 | 6 | 14 | 16 |
